Silence Therapeutics PLC (LSE:SLN) - Overview

Stock Report

Silence Therapeutics PLC SLN

Last Price
GBX111.50

Day Change
0.00|0.00%

As of 01/12/2016
08:46:46 GMT | GBX
Minimum 15 Minutes Delay.

Last Close111.50p
Day Range110.00 - 110.00
Mkt Cap77.83Mil
52-Wk Range96.63 - 171.20
Yield %0.00
ISINGB00B9GTXM62
Volume1,500
P/E-12.29
P/SInfinity
P/CF-8.84

Share Price

Total Returns 02/12/2016

 Chg (%)  
More ...
Silence Therapeutics PLC-3.46 
FTSE 100 TR GBP-1.21
 
Financials
201320142015
More ...
Income Statement
Turnover0.120.020.00
Operating Profit-9.07-12.13-9.77
Net Profit-9.00-11.09-6.65
Reported EPS-20.00-22.00-10.40
Balance Sheet
Current Assets21.2822.2353.55
Non Current Assets8.027.548.00
Total Assets29.3029.7761.55
Current Liabilities1.722.011.12
Total Liabilities1.722.011.12
Total Equity27.5827.7660.43
Cash Flow
Operating Cash Flow-6.76-9.46-8.26
Net Change in Cash6.931.1935.22
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2016-11.83-15.08--7.40---
2017-13.90-17.39--6.41---
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
18/04/2016PurchaseDr. Stephen Parker123.316,4787,988.00
18/04/2016PurchaseAli Mortazavi125.00160,000200,000.00

Company Profile

Silence Therapeutics PLC and its subsidiaries are engaged in the discovery, development and delivery of novel therapeutics for the treatment of serious diseases.
 

Sector

Biotechnology

Market Position

943 of 1865 Companies

Index

FTSE AIM All Share

Outlook

(27/09/2016) "...we look to the future with great confidence"

Next Event 31/12/2016

Next year end (to be reported)
Ratios
CompSecMkt
More ...
PER (E)-6.4813.1416.27
Div Yld (E)0.004.184.36
PEG (E)0.000.360.00
ROCE-15.96206.9680.66
Op Mrgn0.00-17.09-14.86
EPS Grwth0.009.6525.03
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanDr. Stephen Parker
Chief Executive OfficerAli Mortazavi
Chief Financial OfficerDavid Ellam
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2016 Morningstar. All rights reserved.